United Therapeutics' Soft-Mist Inhaler for Tyvaso Could Boost Market Share, RBC Says

MT Newswires Live

02/27

United Therapeutics' (UTHR) development of a soft-mist inhaler for treprostinil or Tyvaso could boost the company's market share as the future of Tyvaso dry powder inhaler remains unclear, RBC Capital Markets said Wednesday.

The company reported Q4 earnings of $7.70 per diluted share, up from $6.19 a year earlier, as revenue increased to $790.2 million from $735.9 million. RBC said Q4 revenue from both the Tyvaso franchise and Tyvaso dry powder inhaler, or DPI, missed market expectations.

The "surprise announcement" of the soft-mist inhaler or SMI is a positive and could improve the profile of the company's inhaled Tyvaso franchise versus competitors, according to RBC. United Therapeutics claimed that the SMI could reduce cough and improve convenience, while maintaining efficacy, RBC noted.

SMI remains under development and United Therapeutics expects to complete filings this year for a potential launch in 2027, the brokerage said.

RBC raised its price target on United Therapeutics to $643 from $587, with an outperform rating.

Price: 498.49, Change: -36.62, Percent Change: -6.84

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2614247500"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614247500\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614247500?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 01:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614247500","market":"hk","top_or_hot":-1,"title":"United Therapeutics' Soft-Mist Inhaler for Tyvaso Could Boost Market Share, RBC Says","media":"MT Newswires Live","content":"<html><body><p> United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (UTHR) development of a soft-mist inhaler for treprostinil or Tyvaso could boost the company's market share as the future of Tyvaso dry powder inhaler remains unclear, RBC Capital Markets said Wednesday.</p><p>The company reported Q4 earnings of $7.70 per diluted share, up from $6.19 a year earlier, as revenue increased to $790.2 million from $735.9 million. RBC said Q4 revenue from both the Tyvaso franchise and Tyvaso dry powder inhaler, or DPI, missed market expectations.</p><p>The \"surprise announcement\" of the soft-mist inhaler or SMI is a positive and could improve the profile of the company's inhaled Tyvaso franchise versus competitors, according to RBC. United Therapeutics claimed that the SMI could reduce cough and improve convenience, while maintaining efficacy, RBC noted.</p><p>SMI remains under development and United Therapeutics expects to complete filings this year for a potential launch in 2027, the brokerage said.</p><p>RBC raised its price target on United Therapeutics to $643 from $587, with an outperform rating.</p><p>Price: 498.49, Change: -36.62, Percent Change: -6.84</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>United Therapeutics' Soft-Mist Inhaler for Tyvaso Could Boost Market Share, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnited Therapeutics' Soft-Mist Inhaler for Tyvaso Could Boost Market Share, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-27 01:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (UTHR) development of a soft-mist inhaler for treprostinil or Tyvaso could boost the company's market share as the future of Tyvaso dry powder inhaler remains unclear, RBC Capital Markets said Wednesday.</p><p>The company reported Q4 earnings of $7.70 per diluted share, up from $6.19 a year earlier, as revenue increased to $790.2 million from $735.9 million. RBC said Q4 revenue from both the Tyvaso franchise and Tyvaso dry powder inhaler, or DPI, missed market expectations.</p><p>The \"surprise announcement\" of the soft-mist inhaler or SMI is a positive and could improve the profile of the company's inhaled Tyvaso franchise versus competitors, according to RBC. United Therapeutics claimed that the SMI could reduce cough and improve convenience, while maintaining efficacy, RBC noted.</p><p>SMI remains under development and United Therapeutics expects to complete filings this year for a potential launch in 2027, the brokerage said.</p><p>RBC raised its price target on United Therapeutics to $643 from $587, with an outperform rating.</p><p>Price: 498.49, Change: -36.62, Percent Change: -6.84</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1699723380.USD","symbol_name":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2614247500","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614247500","pubTimestamp":1772125988,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"United Therapeutics'  development of a soft-mist inhaler for treprostinil or Tyvaso could boost the company's market share as the future of Tyvaso dry powder inhaler remains unclear, RBC Capital Markets said Wednesday.The company reported Q4 earnings of $7.70 per diluted share, up from $6.19 a year earlier, as revenue increased to $790.2 million from $735.9 million. RBC said Q4 revenue from both the Tyvaso franchise and Tyvaso dry powder inhaler, or DPI, missed market expectations.The \"surprise announcement\" of the soft-mist inhaler or SMI is a positive and could improve the profile of the company's inhaled Tyvaso franchise versus competitors, according to RBC. United Therapeutics claimed that the SMI could reduce cough and improve convenience, while maintaining efficacy, RBC noted.SMI remains under development and United Therapeutics expects to complete filings this year for a potential launch in 2027, the brokerage said.RBC raised its price target on United Therapeutics to $643 from ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","BK4139":"生物科技","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4532":"文艺复兴科技持仓","UTHR":"美国联合医疗"},"translate_title":"加拿大皇家银行表示，United Therapeutics的Tyvaso软雾吸入器可能会提高市场份额","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UTHR":1.5},"content_text":"United Therapeutics' (UTHR) development of a soft-mist inhaler for treprostinil or Tyvaso could boost the company's market share as the future of Tyvaso dry powder inhaler remains unclear, RBC Capital Markets said Wednesday.The company reported Q4 earnings of $7.70 per diluted share, up from $6.19 a year earlier, as revenue increased to $790.2 million from $735.9 million. RBC said Q4 revenue from both the Tyvaso franchise and Tyvaso dry powder inhaler, or DPI, missed market expectations.The \"surprise announcement\" of the soft-mist inhaler or SMI is a positive and could improve the profile of the company's inhaled Tyvaso franchise versus competitors, according to RBC. United Therapeutics claimed that the SMI could reduce cough and improve convenience, while maintaining efficacy, RBC noted.SMI remains under development and United Therapeutics expects to complete filings this year for a potential launch in 2027, the brokerage said.RBC raised its price target on United Therapeutics to $643 from $587, with an outperform rating.Price: 498.49, Change: -36.62, Percent Change: -6.84","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}